Shares of Exact Sciences (EXAS) are up over 20% today. The maker of Cologuard, a colon cancer DNA screening test, preannounced earnings which handily beat Wall Street’s expectations.

There may be more upside from here, says Hedgeye Healthcare analyst Tom Tobin (he’s been bullish on the stock since last summer). Exact Sciences has thus far undersold the benefits of Cologuard.

Here’s a brief rundown of the quarter.

Exact Sciences added 9,500 new physicians who were recommending Cologuard in the fourth quarter, an increase of +120% year-over-year. That was enough to help beat quarterly revenue numbers, posting $35.1 million or growth of 114% year-over-year. EXAS closed out 2016 with 244,000 tests ordered, of which 82,000 occurred in 4Q16 compared to their guidance of 78,000.

“There’s still a large untapped market opportunity in terms of prescribing physicians” for Exact Sciences, Tobin says in the video above. Our Healthcare team’s analysis suggests that Cologuard is now just 20% penetrated into its total addressable provider market.

“We think the marketing opportunity here and execution opportunity here could be big, given that [Cologuard] tests are pretty good and we’ve got a lot of good feedback from physicians,” Tobin says.


You're Leaving Hedgeye Risk Management...

By selecting this link, you are now leaving the Hedgeye Risk Management (“HRM”) website. The following website contains information concerning investment products managed by Hedgeye Asset Management (“HAM”), an affiliate of HRM, or a firm partnering with HAM, and is subject to HAM’s Privacy Policy. As a separate legal entity, all HAM asset management services are made independently by portfolio managers at HAM and, as such, funds may vary from HRM research.

HRM is not responsible for the accuracy or completeness of information on external websites. HRM does not make any representation regarding the advisability of investing in any investment product or any particular investment advisory. Any opinions or recommendations from linked websites are solely those of our affiliate and are not the opinions or recommendations of HRM.

HRM DOES NOT PROVIDE PERSONALIZED INVESTMENT ADVICE OR ENGAGE IN ANY ASSET MANAGEMENT SERVICE. LASTLY, THIS LINK IS NOT AN OFFER TO BUY OR A SOLICITATION TO SELL ANY SECURITY OR INVESTMENT PRODUCT, OR THE SOLICITATION OF ANY ADVISORY SERVICES.